NEW YORK (GenomeWeb News) – Pressure BioSciences has filed with US regulators for a direct offering of a maximum of $5 million of its Series F preferred stock.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission on Friday, Pressure Bio said it plans to offer 5,000 shares of its Series F preferred stock at $1,000 per share. The stock is being offered directly to one or more accredited investors.

Moody Capital Solutions is acting as placement agent on the offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.